TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11893841

Group type: EXPERIMENTAL
Intervention: Rivastigmine (Exelon)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 10205637

Group type: EXPERIMENTAL
Intervention: Folifer-Z tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fefol-Z capsules
Number of subjects: 30
Study: 7697305

Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment as an intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurses' experiences in quality-of-life assessment
Number of subjects: 0
Study: 2472826

Group type: EXPERIMENTAL
Intervention: Chemotherapy (streptozotocin plus 5-fluorouracil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Somatostatin analogue SMS 201-995
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IFN-1/2 (2b) or IntronA
Number of subjects: 30
Study: 48191

Group type: EXPERIMENTAL
Intervention: Escherichia coli 075:K100:H5
Number of subjects: 16
Study: 31718427

Group type: EXPERIMENTAL
Intervention: Sofia 6‐French PLUS catheter
Number of subjects: 54
Study: 31537372

Group type: EXPERIMENTAL
Intervention: MAISHA intervention (10 sessions)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Control (wait-listed for intervention)
Number of subjects: 1049
Study: 28533200

Group type: EXPERIMENTAL
Intervention: Beliefs about Medicines Questionnaire (quantitative assessment)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Qualitative interviews (thematic analysis)
Number of subjects: 196
Study: 26522042

Group type: EXPERIMENTAL
Intervention: Clinpro XT light-curable fluoride varnish applied to buccal surfaces adjacent to brackets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 38
Study: 23053214

Group type: EXPERIMENTAL
Intervention: Roll-plate technique
Number of subjects: 199

Group type: COMPARATOR
Intervention: Sonication technique
Number of subjects: 199

Group type: COMPARATOR
Intervention: Urine culture
Number of subjects: 199
Study: 20528216

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 μg per day)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 19408858

Group type: EXPERIMENTAL
Intervention: Haemorheopheresis (cascade filtration), 8 cycles in 10 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (natural course of ARMD)
Number of subjects: 32
Study: 17536122

Group type: EXPERIMENTAL
Intervention: Moderate multivitamin and mineral supplementation (vitamin C 150.0 mg/day, vitamin E 24.0 mg/day, beta-carotene 4.8 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15779316

Group type: EXPERIMENTAL
Intervention: NaOCl + SB
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: NaOCl + PB
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: NaOCl + CSE
Number of subjects: 45

Group type: COMPARATOR
Intervention: SB
Number of subjects: 45

Group type: COMPARATOR
Intervention: PB
Number of subjects: 45

Group type: COMPARATOR
Intervention: CSE
Number of subjects: 45
Study: 16144560

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Autologous fascia lata (Lata)
Number of subjects: 67
Study: 11376277

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of SH U 508A (1 mL/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bolus injection of SH U 508A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Individualized infusion of SH U 508A
Number of subjects: 12
Study: 9231473

Group type: EXPERIMENTAL
Intervention: Pragmatic eradication of Helicobacter Pylori
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8433354

Group type: EXPERIMENTAL
Intervention: Detection behaviors (e.g., cholesterol check)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promotion behaviors (e.g., eating a low-fat diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information and emotional persuasive messages
Number of subjects: 0
Study: 3691441

Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde (FA) exposure for 40 min with mild exercise regimen (450 kpm/min) after 5 min in chamber
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0 ppm formaldehyde (FA) exposure for 40 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde (FA) exposure with symptom diary and PEFR measurements recorded for 24 hr after exposure
Number of subjects: 15
Study: 29843755

Group type: EXPERIMENTAL
Intervention: G + MK (gemcitabine + MK-0646)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: G + MK + E (gemcitabine + MK-0646 + erlotinib)
Number of subjects: 45

Group type: COMPARATOR
Intervention: G + E (gemcitabine + erlotinib)
Number of subjects: 45
Study: 26024744

Group type: EXPERIMENTAL
Intervention: Case management program with telephone follow-up sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 25592781

Group type: EXPERIMENTAL
Intervention: IFN and low doses of MTX
Number of subjects: 377

Group type: COMPARATOR
Intervention: IFN and all trans-retinoid acid
Number of subjects: 377
Study: 23418958

Group type: COMPARATOR
Intervention: Standard cardiovascular treatment according to Dutch guidelines
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Counselling based on self-monitoring (pedometer, weighing scale and/or blood pressure device) by trained practice nurses
Number of subjects: 179
Study: 22029856

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 mcg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18203182

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ECMO
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 23
Study: 16995545

Group type: EXPERIMENTAL
Intervention: Customized aspheric treatment zone (CATz)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 27
Study: 14722370

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Twice weekly iron supplementation (60 mg)
Number of subjects: 244
Study: 11398594

Group type: EXPERIMENTAL
Intervention: Eutrophic newborns group (33 women)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Hypotrophic newborns group (36 women)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (30 healthy not pregnant women)
Number of subjects: 99
Study: 9163024

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) on cerebrospinal fluid (CSF) and brain samples
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Antiviral treatment with aciclovir
Number of subjects: 260
Study: 1351888

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once daily for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 6584561

Group type: EXPERIMENTAL
Intervention: Carminomycin (18 mg/m2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 4'-epidoxorubicin (90 mg/m2)
Number of subjects: 63
Study: 30391573

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with 45 Gy/30 twice-daily fractions over 19 days
Number of subjects: 490

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy with 66 Gy/33 once-daily fractions over 45 days
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (both groups)
Number of subjects: 490
Study: 29031390

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (280mg DHA and 110mg EPA)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 420
Study: 25654629

Group type: EXPERIMENTAL
Intervention: Individualized program including exercise therapy plus risk factor modification for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Quadriceps strengthening exercise only for 12 weeks
Number of subjects: 53
Study: 23108015

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to music once a day for 4 consecutive weeks using two types of CDs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60
Study: 20880729

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Simvastatin 40 mg plus placebo
Number of subjects: 18
Study: 19781096

Group type: EXPERIMENTAL
Intervention: Continuous case management intervention
Number of subjects: 842

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 842
Study: 17542814

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care with the father
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cot care (control)
Number of subjects: 29
Study: 15235556

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine combined with sufentanil at a dose of 0.5 microg/ml(‐1) (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine combined with sufentanil at a dose of 0.75 microg/ml(‐1) (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine combined with sufentanil at a dose of 1 microg/ml(‐1) (group C)
Number of subjects: 45
Study: 12390994

Group type: EXPERIMENTAL
Intervention: Infants with meconium stained amniotic fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10213522

Group type: EXPERIMENTAL
Intervention: Misoprostol exposure
Number of subjects: 86
Study: 7844872

Group type: EXPERIMENTAL
Intervention: Optic nerve decompression surgery
Number of subjects: 244

Group type: COMPARATOR
Intervention: Careful follow-up
Number of subjects: 244
Study: 2169378

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration maintained at 4.5 mmol/l (euglycaemia)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Blood glucose concentration maintained at 3.5 mmol/l (mild hypoglycaemia)
Number of subjects: 10
Study: 224997

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cyclophosphamide, doxorubicin, and imidazole carboximide)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cycle-active therapy (vincristine, hydroxyurea, and methotrexate)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 288
Study: 6660827

Group type: EXPERIMENTAL
Intervention: Normal saline solution, 10 ml per 1000 g of patient weight injected into the peritoneal cavity before closing the incision.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (no saline solution injection).
Number of subjects: 173
Study: 31564256

Group type: EXPERIMENTAL
Intervention: Crushing technique
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lateral laminectomy
Number of subjects: 43
Study: 29398576

Group type: EXPERIMENTAL
Intervention: Real tVNS treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham tVNS treatment
Number of subjects: 41
Study: 26614422

Group type: EXPERIMENTAL
Intervention: G1: 5' at 9±1°C
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: G2: 5' at 14±1°C
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: G3: 15' at 9±1°C
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: G4: 15' at 14±1°C
Number of subjects: 100

Group type: COMPARATOR
Intervention: CG: control group
Number of subjects: 100
Study: 25152605

Group type: EXPERIMENTAL
Intervention: NSAID-muscovite group (3 g of muscovite + 75 mg slow-release diclofenac, twice daily for 14 d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: NSAID control group (75 mg slow-release diclofenac, twice daily for 14 d)
Number of subjects: 30
Study: 22985580

Group type: EXPERIMENTAL
Intervention: Serum total P1NP
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Serum β‐CTX
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3
Number of subjects: 136

Group type: COMPARATOR
Intervention: Bone mineral density (BMD)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Serum total P1NP and β‐CTX
Number of subjects: 136
Study: 20016013

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate ([(58)Fe]ferrous sulfate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate ([(57)Fe]ferrous fumarate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Corrected fractional iron absorption in children
Number of subjects: 36
Study: 18817237

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 15630172

Group type: EXPERIMENTAL
Intervention: Liposomal lactoferrin, 319 mg per day for four weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-liposomal lactoferrin
Number of subjects: 15
Study: 11789395

Group type: EXPERIMENTAL
Intervention: Perindopril + indapamide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 0
Study: 9435041

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1.5 g/day)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Meropenem (3.0 g/day)
Number of subjects: 287
Study: 8352687

Group type: EXPERIMENTAL
Intervention: Macular heterotopia
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Retinal fold
Number of subjects: 69
Study: 2442551

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg (increased to 80 mg if necessary)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Atenolol 50 mg (increased to 200 mg if necessary)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 or 25 mg added after 12 weeks if necessary
Number of subjects: 490
Study: 28899914

Group type: EXPERIMENTAL
Intervention: Strenuous military training (4-day, 51-km cross-country ski march)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Strenuous military training
Number of subjects: 25
Study: 27769293

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (weekend group session at a spa resort, expert conferences, focus group activities, supervised by a psychotherapist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 12
Study: 24619576

Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on the laryngoscope blade (group L)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on the trachea (group V)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on both the laryngoscope blade and trachea (group LV)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No lidocaine (group C)
Number of subjects: 72
Study: 22039086

Group type: EXPERIMENTAL
Intervention: Capecitabine + Bevacizumab (CB)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Capecitabine + Bevacizumab + Mitomycin C (CBM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Capecitabine (C)
Number of subjects: 99
Study: 20618964

Group type: EXPERIMENTAL
Intervention: Chicory root extract (600 mg/day, 1200 mg/day, 1800 mg/day for 1 month)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17519819

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (CT scan, fibreoptic bronchoscopy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple follow-up (clinical examination, chest x-ray)
Number of subjects: 0
Study: 16259626

Group type: EXPERIMENTAL
Intervention: Resource-oriented music therapy (biweekly sessions for three months)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study: 11890453

Group type: COMPARATOR
Intervention: No-stent group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Stent group
Number of subjects: 55
Study: 9532410

Group type: EXPERIMENTAL
Intervention: Interleukin-2-based therapy (same as originally used)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Different interleukin-2-based therapy (including tumor-infiltrating lymphocytes)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Interleukin-2 alone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Surgical metastasectomy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Interleukin-2-based therapy (initial response)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Interleukin-2-based therapy (partial response)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Interleukin-2-based therapy (complete response)
Number of subjects: 159
Study: 7989976

Group type: EXPERIMENTAL
Intervention: 99mTc‐L,L‐EC
Number of subjects: 50

Group type: COMPARATOR
Intervention: 99mTc‐MAG3
Number of subjects: 50

Group type: COMPARATOR
Intervention: 125I‐OIH
Number of subjects: 50
Study: 2455927

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo sodium cromoglycate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo nifedipine
Number of subjects: 7
Study: 31576915

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 27628581

Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention not detailed)
Number of subjects: 449
Study: 26321368

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 75
Study: 25125271

Group type: EXPERIMENTAL
Intervention: Self-administered HIV/HCV risk assessment plus brief intervention about drug misuse and screening for HIV/HCV
Number of subjects: 395

Group type: COMPARATOR
Intervention: Self-administered HIV/HCV risk assessment alone (control)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Both arms offered free combined rapid HIV/HCV screening
Number of subjects: 395
Study: 22842984

Group type: EXPERIMENTAL
Intervention: IORT (20 Gy)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: IORT + WBRT
Number of subjects: 305

Group type: COMPARATOR
Intervention: WBRT (50-56 Gy)
Number of subjects: 305
Study: 19690657

Group type: EXPERIMENTAL
Intervention: Sympathectomy at the T2 level
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sympathectomy at the T3 level
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 17564103

Group type: EXPERIMENTAL
Intervention: Propiverine alone (monotherapy group, n = 52)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propiverine plus urapidil (combination group, n = 48)
Number of subjects: 100
Study: 15637975

Group type: EXPERIMENTAL
Intervention: Integrated system (IntelliClean System from Sonicare and Crest)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual toothbrush with conventional toothpaste
Number of subjects: 100
Study: 11466989

Group type: EXPERIMENTAL
Intervention: Physical training programme (twice a week for three months)
Number of subjects: 25
Study: 9465812

Group type: EXPERIMENTAL
Intervention: Preoperative administration of two injections of leuprolide acetate 28 days apart (group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Direct surgery (group B)
Number of subjects: 67
Study: 7486614

Group type: EXPERIMENTAL
Intervention: CNS 1102 (aptiganel hydrochloride) administered in doses of up to 100 micrograms/kg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CNS 1102 administered as a 15-minute intravenous infusion, a 15-minute loading intravenous infusion followed by a 4-hour maintenance infusion, or as a fixed-dose intravenous bolus over 90 seconds
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CNS 1102
Number of subjects: 55
Study: 2650735

Group type: EXPERIMENTAL
Intervention: 60 g margarine added to soup
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 60 g margarine added to mashed potato
Number of subjects: 6
Study: 964056

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with neomycin and bacitracin for 4 days preoperatively
Number of subjects: 108

Group type: COMPARATOR
Intervention: Mechanical and dietary preparation only (Control)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with neomycin and bacitracin
Number of subjects: 108
Study: 31059146

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (lower dose) in secondary adrenal insufficiency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (higher dose) in secondary adrenal insufficiency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stable hydrocortisone and fludrocortisone therapy in primary adrenal insufficiency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Primary adrenal insufficiency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Secondary adrenal insufficiency with higher endogenous cortisol production
Number of subjects: 39
Study: 28596150

Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) + Alpha-lipoic acid (ALA) combination
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pregabalin (PGB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 54
Study: 24651301

Group type: EXPERIMENTAL
Intervention: AryoSeven (30 μg/kg, intravenously per week for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NovoSeven (30 μg/kg, intravenously per week for 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AryoSeven
Number of subjects: 0

Group type: COMPARATOR
Intervention: NovoSeven
Number of subjects: 0
Study: 22364530

Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste and gel (Elmex(®))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 0.12% spray-chlorhexidine (Perio-Aid(®))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Brush teeth without toothpaste (Control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive status and requirement for assistance
Number of subjects: 26
Study: 20880042

Group type: EXPERIMENTAL
Intervention: Immediate U.S.$25 cash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate U.S.$25 check
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promised U.S.$25 check
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promised U.S.$25 check requiring an SSN
Number of subjects: 0